Arsenic triggers heart senescence in mice while quercetin counteracts the damage
Exposure to environmental arsenic caused heart dysfunction via the p53 and p21 pathway, which quercetin treatment reversed in cultured rat cardiomyoblasts.
Toxicology and applied pharmacology · Wang H et al. · Paper published 26 Sep 2026
In male C57BL/6 mice and rat cardiomyoblasts, researchers examined how environmental arsenic promotes cardiac aging and whether quercetin can mitigate the damage. Three-week-old mice drank water containing sodium arsenite for six weeks, with 22-month-old mice serving as natural aging controls. Arsenic exposure induced left ventricular systolic and diastolic dysfunction, myocardial fibrosis, behavioral deficits, and elevated P53 and P21 levels. In rat cardiomyoblasts, arsenic directly bound a cysteine residue on p53, driving cellular senescence through the p53/p21 axis. Arsenic also increased senescence-associated beta-galactosidase activity and raised levels of P53, P21, and IL-6. Subsequent treatment with quercetin reversed these senescence markers in cells and downregulated overactivated targets, including TP53, AKT1, and EGFR.
Why it matters
The findings show that environmental toxicant exposure can directly activate cellular senescence pathways in the heart, mimicking natural cardiovascular aging. Identifying shared molecular drivers of chemical toxicity and aging provides potential targets for interventions that preserve heart function.
Caveats
The study was conducted in young male mice and cultured rat cells, so the findings may not translate to humans or female physiology. In addition, quercetin was tested as an intervention only in cell culture rather than in whole animals.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Myocardial senescence as a mechanistic endpoint of arsenic cardiotoxicity: Cysteine-associated p53/p21 activation and reversal by quercetin
Wang H, Wang Y, Huang S et al.
Toxicology and applied pharmacology · 26 Sep 2026 · Peer-reviewed
- Relevance
- Relevant
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.